IMVT-1402 + IMVT-1402 + Placebo + IMVT-1402
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Myasthenia Gravis
Conditions
Generalized Myasthenia Gravis
Trial Timeline
May 27, 2025 → Dec 1, 2028
NCT ID
NCT07039916About IMVT-1402 + IMVT-1402 + Placebo + IMVT-1402
IMVT-1402 + IMVT-1402 + Placebo + IMVT-1402 is a phase 3 stage product being developed by Immunovant for Generalized Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07039916. Target conditions include Generalized Myasthenia Gravis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07039916 | Phase 3 | Recruiting |
Competing Products
20 competing products in Generalized Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |